Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) and Comera Life Sciences (NASDAQ:CMRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Valuation & Earnings
This table compares Actinium Pharmaceuticals and Comera Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actinium Pharmaceuticals | $90,000.00 | 426.35 | -$48.82 million | ($1.10) | -1.12 |
| Comera Life Sciences | $1.00 million | 0.00 | -$18.00 million | ($0.49) | N/A |
Risk and Volatility
Actinium Pharmaceuticals has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Institutional and Insider Ownership
27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Actinium Pharmaceuticals and Comera Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
| Comera Life Sciences | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent recommendations for Actinium Pharmaceuticals and Comera Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Comera Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
Actinium Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 225.20%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than Comera Life Sciences.
Summary
Comera Life Sciences beats Actinium Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
About Comera Life Sciences
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
